Novo Nordisk’s Struggle: The Eli Lilly Onslaught and Critical Drug Trial Failure

Danish pharmaceutical giant Novo Nordisk, having briefly surpassed LVMH as Europe's most valuable company in 2023, is now struggling to convert its massive success in weight-loss treatments into sustainable long-term growth. The company faces mounting pressure from U.S. rival Eli Lilly and a significant setback in its clinical trials, shaking investor confidence in its pipeline.

The Eli Lilly Threat and a 70% Stock Plunge

The competitive landscape in the obesity and diabetes treatment market has severely impacted Novo Nordisk's stock performance. As the company loses market share to its American competitor Eli Lilly (maker of Mounjaro), their stock trajectories have diverged sharply since 2024:

■Eli Lilly's share price has almost doubled since 2024.

■Novo Nordisk's share price has dropped by 70% over the same period.

■Eli Lilly expects to launch its own weight-loss pill in Europe and the U.K. in early 2027.

Ziltivekimab Trial Failure and Strategic Cost Cutting

A key component of the company's future growth strategy, the cardiovascular drug ziltivekimab—highlighted by Goldman Sachs analysts as a potential market expander—failed in Phase III trials. The drug's inability to prevent heart attacks, strokes, or cardiovascular deaths caused the stock to drop 10% on the news. In response to these headwinds, management has enforced strict cost discipline:

■In September 2025, the company announced the cutting of 9,000 jobs to save $1.2 billion.

■Overall headcount is now 12,000 lower than a year ago.

■The company states it has no plans for a second round of companywide redundancies.

Pivoting to Oral Wegovy and R&D Resilience

Despite the challenges, CFO Karsten Munk Knudsen remains confident in the company's growth assets. Novo Nordisk is focusing heavily on R&D and strategic acquisitions to secure future drivers:

■More than 90% of sales are generated by obesity and diabetes drugs.

■Following EU approval in July, the oral Wegovy pill is set to launch in Germany "soon," with other European countries to follow.

■JPMorgan Global Research forecasts the GLP-1 and weight-loss drug market to reach $200 billion by 2030 (Jefferies predicts a peak of $80 billion).

■The company is actively exploring "bolt-on" acquisitions to strengthen its R&D pipeline.

From an Emerging Markets (EM) desk perspective, Novo Nordisk's current struggles highlight the inherent risk of over-reliance on a single franchise (Wegovy/Ozempic). The steep 70% decline in share price serves as a cautionary tale for EM funds exposed to high-growth European healthcare equities, prompting a reassessment of risk-reward ratios. Furthermore, the potential mega-merger between AstraZeneca and Bristol Myers Squibb—valued at nearly $400 billion—signals a consolidation wave in the sector. This means Novo Nordisk faces not only internal pipeline challenges but also external structural shifts. The critical metric for investors will be how quickly the company can translate its R&D and acquisition strategies into revenue streams that offset the current cash flow pressures and valuation compression.